medigraphic.com

2016, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2016; 54 (4)

End stage renal disease lymphopenia; characterization and clinical correlation

Lepe-Zúñiga JL, Morales-Molina P, García-Nandayapa GA

Language: Spanish
References: 27
Page: 446-453
PDF size: 94.22 Kb.


ABSTRACT

Background: Patients with End Stage Renal Disease (ESRD), defi ned as those in Stage 5 of the Kidney Disease Outcome Quality Initiative (KDOQI) classifi cation, have a number of acquired immune defi ciencies secondary to the uremic stage, among them lymphopenia. In the present report, we retrospectively characterized the peripheral blood lymphocyte counts in a group of patients with ESRD and we related lymphopenia to their biochemical parameters and to the presence or absence of infections.
Methods: Medical records from 190 patients in ESRD were selected from 282 medical records of patients being treated between February 2008 and November 2012 for kidney failure at different stages. A number of variables, including lymphocyte counts, biochemical parameters and infections, were analyzed at two different time points: Before and during dialysis.
Results: ESRD patients analyzed had a well defi ned peripheral blood hematological pattern, characterized by severe chronic anemia, normal or elevated leukocyte count and normal or below normal lymphocyte count. The degree of hematological changes correlated with the depth of renal dysfunction and improved with dialysis along with the improvement of urea and creatinine values.
Conclusions: Lymphopenia was present in around half ESRD patients and was associated with increased infections, but they were of the same type as those present in ESRD patients without lymphopenia. Infections were different as those commonly associated with other immune deficiency lymphopenias. The implications of these findings are discussed.


REFERENCES

  1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classifi cation and Stratifi cation. Am J Kidney Dis 39:S1-S266,2002 (suppl 1).

  2. Cueto-Manzano AM: Peritoneal dialysis in Mexico. Kidney International, 2003;63 Supplement 83:S90-S92.

  3. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O’Shea S, Owen Jr WF, Lowrie EG. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003;18:1167- 1173. DOI: 10.1093/ndt/gfg066

  4. Papadimitriou M, Baker LRI, Seitanidis B, Sevitt LH, Kulatilakeii AE: White Blood Count in Patients on Regular Haemodialysis. British Medical.Journal 1969;4:67-69.

  5. Agarwal R, Light RP. Patterns and Prognostic Value of Total and Differential Leukocyte Count in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2011;6: 1393-1399. DOI: 10.2215/CJN.10521110.

  6. Caro J, Erslev AJ. Anemia of Chronic Renal Failure. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U. Williams Hematology. 6th ed. New York, NY: McGraw Hill. 2001:399-405.

  7. Babit JL, Lin HY. Mechanisms of Anemia in CKD. J Am Soc Nephrol 2012; 23(10):1631-1634. Published online Aug 30, 2012. DOI: 10.1681/ASN.2011111078

  8. Babitt JL, Lin, HY. Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD Am J Kidney Dis. 2010; 55(4): 726–741. DOI:10.1053/j. ajkd.2009.12.030.

  9. Vanholder R1, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classifi cation, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43.

  10. Daniels JC, Remmers AR Jr, Sarles HE, Fish JC, Cobb EK, Levin WC, Ritzmann SE. Interpretation of nucleic acid synthesis. Studies in renalfailure lymphocytes. J Reticuloendothel Soc. 1970 Sep;8(3):240-7.

  11. Stewart E, Miller TE. Host Immune Status In Uraemia. II. Serum Factors and Lymphocyte Transformation. Clin. Exp. Immunol. 1980;41:123-129.

  12. Carvounis CP, Manis T, Coritsidis G, Dubinsky M, Serpente P. Total Lymphocyte Count: a Promising Prognostic Index of Mortality in Patients on CAPD Peritoneal Dialysis International, 2000 Vol. 20, pp. 33-38.

  13. Cueto–Manzano AM, Quintana–Piña E, Correa– Rotter R. Long-Term CAPD Survival and Analysis of Mortality Risk Factors: 12-Year Experience of a Single Mexican Center. Peritoneal Dialysis International 2003 Vol 21, pp. 148-153.

  14. Daniels JC, Sakai H, Remmers Jr AR, Sarles HE, Fish JC, Cobb EK, Levin WC, Ritzmann SE: In vitro reactivity of human lymphocytes in chronic uraemia: Analysis and Interpretation. Clin Exp Immunol 1971; 8:213-227.

  15. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R Vaziri ND: Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010;25: 205–212 DOI: 10.1093/ndt/gfp397

  16. Yoon JW, Gollapudi S, Pahl MV, VaziriND. Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney International 2006 70:371-376.

  17. Betjes MGH, Langerak AW, van der Spek A, de Wit EA, Litjens NHR. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney International 2011;80, 208–217. DOI:10.1038/ki.2011.110.

  18. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of Uremia on Structure and Function of Immune System. J Ren Nutr. 2012;22(1):149-156. DOI:10.1053/j. jrn.2011.10.020

  19. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of Immune Dysfunction in Endstage Renal Disease. Clin J Am Soc Nephrol 2008; 3:1526-1533. DOI: 10.2215/CJN.00950208

  20. Cole TS, Cant AJ. Clinical experience in T cell defi - cient patients. Allergy, Asthma & Clinical Immunology 2010, 6:9. Disponible en: http://www.aacijournal.com/ content/6/1/9

  21. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodefi ciency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011; 127(6):1329- 41.e2; quiz1342-3. DOI: 10.1016/j.jaci.2011.02.047.

  22. Dropulic LK, Cohen JI. Severe Viral Infections and Primary Immunodefi ciencies. Clin Infect Dis. 2011 Nov;53(9):897-909. DOI: 1093/cid/cir610. Epub 2011 Sep 29.

  23. Coelho L, Veloso VG, Grinsztejn B, Luz PM. Trends in overall opportunistic illnesses, Pneumocystis carinii pneumonia, cerebral toxoplasmosis and Mycobacterium avium complex incidence rates over the 30 years of the HIVepidemic: a systematic review. Braz J Infect Dis 2014;18(2):196-10.

  24. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney International 2002;62:1524-538.

  25. Stenvinkel P, Bárány P: Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to infl ammation and oxidative stress. Nephrol Dial Transplant 2002;17 Suppl 5:32-7.

  26. Pecoits-Filho R, Bárány P, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-688.

  27. Stenvinkel P. Infl ammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17 [Suppl 8]:33-8.




2020     |     www.medigraphic.com